Arrowhead Pharmaceuticals, Inc. (ARWR) P/E Ratio History
Deep ValueTrading at -6706.6x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 1999–2026
Loading P/E history...
P/E Ratio Analysis
As of June 23, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) trades at a price-to-earnings ratio of -6706.6x, with a stock price of $81.82 and trailing twelve-month earnings per share of $-2.11.
The current P/E is 10366% below its 5-year average of 65.3x. Over the past five years, ARWR's P/E has ranged from a low of 0.6x to a high of 280.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, ARWR trades at a 30419% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, ARWR trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ARWR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ARWR Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ARWR P/E vs Peers
RNA and Genome Editing Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $37B | 119.4 | - | +207%Best | |
| $63B | 14.7Lowest | 2.32 | +8% | |
| $8B | 26.8 | 1.17Best | -25% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ARWR Historical P/E Data (1999–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | Dec 31 2025 | $66.39 | $1.54 | 43.1x | -34% |
| FY2020 Q2 | - | $28.77 | $0.10 | 280.7x | +330% |
| FY2020 Q1 | - | $63.43 | $0.54 | 116.9x | +79% |
| FY2019 Q4 | Sep 30 2019 | $28.18 | $0.70 | 40.3x | -38% |
| FY2019 Q3 | Jun 30 2019 | $26.50 | $0.47 | 56.4x | -14% |
| FY2019 Q2 | Mar 31 2019 | $18.35 | $0.08 | 229.4x | +251% |
| FY2004 Q3 | Jun 30 2004 | $70.00 | $12.51 | 5.6x | -91% |
| FY2004 Q2 | Mar 31 2004 | $45.00 | $6.49 | 6.9x | -89% |
| FY2000 Q2 | Mar 31 2000 | $121.55 | $50.02 | 2.4x | -96% |
| FY2000 Q1 | Dec 31 1999 | $35.75 | $54.51 | 0.7x | -99% |
| FY1999 Q4 | - | $58.50 | $59.00 | 1.0x | -98% |
| FY1999 Q3 | Jun 30 1999 | $39.00 | $63.00 | 0.6x | -99% |
Average P/E for displayed period: 65.3x
Full Stock Analysis
Deep dive into ARWR consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
27+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ARWR — Frequently Asked Questions
Quick answers to the most common questions about buying ARWR stock.
What is ARWR's P/E ratio?
Arrowhead Pharmaceuticals, Inc. (ARWR) trailing twelve-month P/E ratio is -6706.6x, based on TTM diluted EPS of $-2.11. The 5-year average P/E is 65.3x and the historical range spans 0.6x to 280.7x.
Is ARWR stock overvalued or undervalued?
ARWR trades at -6706.6x P/E, below its 5-year average of 65.3x. At the 0th percentile of its historical range (0.6x–280.7x), the stock is priced at a discount to its own history.
Is ARWR stock expensive?
No, ARWR is not expensive on a historical basis. The current P/E of -6706.6x is below the 5-year average of 65.3x and sits at the 0th percentile of its valuation range.
What is ARWR's historical P/E range?
Over the past 5 years, ARWR's P/E ratio has ranged from 0.6x to 280.7x, with a median of 40.3x and an average of 65.3x. The current P/E of -6706.6x places the stock at the 0th percentile of this range. Full historical data spans 1999–2026.
How does ARWR's P/E compare to the S&P 500?
ARWR trades at -6706.6x P/E versus the S&P 500 median of 24.4x. The 27586% discount to the market suggests lower growth expectations or perceived higher risk.
How does ARWR's valuation compare to Healthcare peers?
Arrowhead Pharmaceuticals, Inc. P/E of -6706.6x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ARWR's PEG ratio?
ARWR PEG ratio is N/A, based on a P/E of -6706.6x and EPS growth of 99.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ARWR's earnings yield?
ARWR earnings yield is N/A, the inverse of its -6706.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.